Literature DB >> 7791081

Antiproliferative effects of delta opioids on highly purified CD4+ and CD8+ murine T cells.

N A Shahabi1, B M Sharp.   

Abstract

Numerous studies have shown that opioids modulate the proliferative response of mixed splenocytes to T cell mitogens. To identify the T cell subpopulations affected by opioids, splenocytes from C57BL/6 and CD1 mice were separated using a fluorescent activated cell sorter (FACS) to obtain 98 to 99% pure populations of either CD4+ or CD8+ T cells. Cells were stimulated to proliferate in serum-free medium by cross-linking the T cell receptor using plate-coated anti-CD3-epsilon, then 3H-thymidine uptake and cell number were measured at 48 and 72 hr. [D-Ala2]-deltorphin 1 (deltorphin) dose-dependently inhibited the proliferation of C57BL/6 CD4+ T cells by approximately 50%. This effect was maximal when cells were preincubated with deltorphin 60 min before activation, whereas deltorphin was ineffective when added at the time of activation. Similarly, [D-Ala2]-Met-Enkephalinamide (DAME) 10(-11) to 10(-7) M inhibited CD4+ T cell proliferation. Naltrindole 10(-12) M abolished the antiproliferative effect of 10(-7) M deltorphin on CD4+ T cells. Proliferation of CD8+ T cells from C57BL/6 mice also was dose-dependently inhibited by deltorphin. At all concentrations to deltorphin, the antiproliferative effects were greater after 48 compared to 72 hr in culture. The effect of deltorphin and DAME on secretion of the T cell growth factor, IL-2, was determined by ELISA analysis of supernatants obtained from CD4+ T cells after 48-hr culture. Deltorphin showed a biphasic effect: 10(-11) M enhanced IL-2 secretion, whereas higher concentrations (10(-9)-10(-7) M) were inhibitory.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7791081

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Detection and function of opioid receptors on cells from the immune system.

Authors:  J M Bidlack
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

Review 2.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

3.  Influence of endogenous opioid systems on T lymphocytes as assessed by the knockout of mu, delta and kappa opioid receptors.

Authors:  Ali G Karaji; David Reiss; Audrey Matifas; Brigitte L Kieffer; Claire Gavériaux-Ruff
Journal:  J Neuroimmune Pharmacol       Date:  2011-09-22       Impact factor: 4.147

Review 4.  Opioid receptors and signaling on cells from the immune system.

Authors:  Jean M Bidlack; Maxim Khimich; Amy L Parkhill; Sarah Sumagin; Baoyong Sun; Christopher M Tipton
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-08       Impact factor: 4.147

5.  Dual signal transduction through delta opioid receptors in a transfected human T-cell line.

Authors:  B M Sharp; N A Shahabi; W Heagy; K McAllen; M Bell; C Huntoon; D J McKean
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

6.  Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene.

Authors:  C Gavériaux-Ruff; H W Matthes; J Peluso; B L Kieffer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

Review 7.  Effects of opioids on the immune system.

Authors:  S Roy; H H Loh
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

8.  Damage of splenic T lymphocyte proliferation and differentiation and its normalization by electroacupuncture in morphine-dependent mice mode.

Authors:  Hong-Yu Li; Rong Zhang; Cai-Lian Cui; Ji-Sheng Han; Liu-Zhen Wu
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-09       Impact factor: 2.629

9.  Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3.

Authors:  Sabrina Tripolt; Heidi A Neubauer; Vanessa M Knab; Dominik P Elmer; Fritz Aberger; Richard Moriggl; Daniela A Fux
Journal:  Neoplasia       Date:  2021-01-16       Impact factor: 5.715

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.